Monte Rosa Therapeutics (GLUE) Assets (2020 - 2026)

Monte Rosa Therapeutics' Assets history runs 7 years deep, the most recent figure standing at $736.4 million for Q1 2026.

• On a quarterly basis, Assets rose 87.29% year-over-year to $736.4 million in Q1 2026; TTM through Mar 2026 was $736.4 million, a 87.29% increase from a year earlier, with the FY2025 full-year figure at $448.7 million, up 2.26% from the prior year.
• Assets improved to $736.4 million in Q1 2026 per GLUE's latest filing, from $448.7 million in the prior quarter.
• Across five years, Assets topped out at $736.4 million in Q1 2026 and bottomed at $252.1 million in Q3 2023.
• The 5-year median for Assets is $346.0 million (2022), against an average of $371.6 million.
• Across the five-year window, Assets slipped 29.5% in 2023 and surged 87.29% in 2026, its largest moves.
• Year by year, Assets stood at $342.4 million in 2022, then declined by 11.28% to $303.8 million in 2023, then jumped by 44.44% to $438.7 million in 2024, then grew by 2.26% to $448.7 million in 2025, then jumped by 64.14% to $736.4 million in 2026.
• Per Business Quant, the three latest GLUE Assets figures stand at $736.4 million (Q1 2026), $448.7 million (Q4 2025), and $459.8 million (Q3 2025).